An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120  by Moseri, Adi et al.
Virology 401 (2010) 293–304
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roAn optimally constrained V3 peptide is a better immunogen than its linear homolog
or HIV-1 gp120☆
Adi Moseri a, Subramanyam Tantry b, Yael Sagi a, Boris Arshava b, Fred Naider b, Jacob Anglister a,⁎
a Department of Structural Biology, Weizmann Institute of Science, Rehovot 76100, Israel
b Department of Chemistry, College of Staten Island of the City University of New York, Staten Island, NY 10314, USA☆ This study was supported by NIH grant GM53329 (JA)
Horowitz Foundation, Gurwin Foundation, the Kimmelma
is theDr. Joseph andRuthOwadesProfessor of Chemistry a
Kurtz Term Professor at the College of Staten Island at the
⁎ Corresponding author. Fax: +972 8 9344136.
E-mail address: Jacob.Anglister@weizmann.ac.il (J. A
0042-6822/$ – see front matter © 2010 Elsevier Inc. A
doi:10.1016/j.virol.2010.03.007a b s t r a c ta r t i c l e i n f oArticle history:
Received 16 December 2009
Returned to author for revision
12 January 2010
Accepted 1 March 2010
Available online 26 March 2010
Keywords:
HIV-1
Vaccine
Neutralizing antibodies
V3 loop
Constrained peptides
Gp120Synthetic peptides offer an attractive option for development of a V3-directed vaccine. However,
immunization with ﬂexible linear peptides may result in an immune response to multiple conformations,
many of which differ from the native conformation of the corresponding region in the protein. Here we show
that optimization of the location of a disulﬁde bond in peptides constrained to mimic the β-hairpin
conformation of the V3, yields an immunogen that elicits a 30-fold stronger HIV-1 neutralizing response in
rabbits compared with the homologous linear V3 peptide. The HIV-1 neutralizing response elicited by the
optimally constrained peptide is also signiﬁcantly stronger than that elicited by a gp120 construct in which
the V3 is exposed. Neutralization of an HIV-1 strain that shares only 72% identity with the immunizing
peptide was demonstrated. The most effective immunogen was also able to neutralize primary isolates that
are more resistant to neutralization such as SS1196 and 6535.and GM22087 (FN), and by the
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Induction of broadly neutralizing antibodies (bnAb) against
diverse HIV-1 strains is critical for the development of a successful
AIDS vaccine. Unfortunately, attainment of such a broadly neutraliz-
ing response by active immunization has proven to be an extremely
difﬁcult task because of the high mutation rate of the virus and the
occlusion of target epitopes prior to the binding of the virus to its
target cells. The recent success of the human trial carried out in
Thailand indicates that despites these obstacles some degree of a
protective immune response can be achieved by active immunization
in humans (Rerks-Ngarm et al., 2009).
The V3 region is a major target for neutralizing antibodies. A recent
immunization study with bivalent trimeric-gp120 demonstrated that
most of the neutralizing activity elicited in rabbits was against V3 and
V4 (Burke et al., 2009). High levels of V3 directed antibodies were also
present in HIV-1 infected patients and in healthy individuals
following gp120 based vaccination (Davis et al., 2009a,b). These
antibodies were broadly reactive, i.e. were able to neutralize a wide
variety of chimeric HIV viruses with different V3 sequences presentedon a HIV-2 scaffold. This is in agreement with previous data showing
that when the different V3 sequences of neutralization-resistant
isolates were presented in the context of the neutralization sensitive
strain SF-162, these chimeric viruses became sensitive to V3
antibodies (Davis et al., 2009a; Zolla-Pazner et al., 2008).
Among HIV-1 neutralizing antibodies, 447-52D derived from an HIV-
1 infected donor is one of themost potent andmost broadly neutralizing
human monoclonal antibodies, and in a study of HIV-1 broadly
neutralizing antibodies 447-52D neutralized 45% of the clade-B isolates
tested and was capable of neutralizing both X4 and R5 viruses as well as
some primary isolates (Binley et al., 2004). To gain insight into the
conformationof theV3 regionpresented to the immune systembyHIV-1,
the structures of V3 peptides bound to HIV-1 neutralizing antibodies
were determinedbyX-ray crystallography (Bell et al., 2008;Dhillon et al.,
2008; Stanﬁeld et al., 2003, 2004, 2006) and by NMR (Rosen et al., 2005;
Sharon et al., 2003; Tugarinov et al., 1999, 2000). All bound V3 structures
revealed a β-hairpin conformation with an RMSD between the hairpin
regions of any two V3 structures in the different complexes ranging
between1.2 and2.5 Å. In some cases differences in thepairing of residues
and in the hydrogen bond network were observed in different antibody-
bound V3-peptides. Our working hypothesis is that the hairpin structure
of the V3 region represents the structure of this domain in the viral
envelope proteins and that antibodies targeting elements of this hairpin
will be effective anti-viral agents.
The critical role for V3 in HIV-1 co-receptor binding restricts its
sequence variation (Rosen et al., 2005, 2006; Sharon et al., 2003;
Stanﬁeld et al., 2004, 2006).Only those sequences that are recognizedby
Table 1
The amino acid sequence of peptides used for immunization and for binding
measurementsa.
Immunogenic peptides
C4–V3L KQIINMWQEVGKAMYA–RPNNNTRKSIHIGPGRAFYTTGEI
C4–V3 K305C–T320C KQIINMWQEVGKAMYA–RPNNNTRCSIHIGPGRAFYTCGEI
C4–V3 K305C–G321C KQIINMWQEVGKAMYA–RPNNNTRCSIHIGPGRAFYTTCEI
C4–V3 R304C–G321C KQIINMWQEVGKAMYA–RPNNNTCKSIHIGPGRAFYTTCEI
C4–V3 T303C–E322C KQIINMWQEVGKAMYA–RPNNNCRKSIHIGPGRAFYTTGCG
C4–V3 T303C–I323C KQIINMWQEVGKAMYA–RPNNNCRKSIHIGPGRAFYTTGEC
C4–V3 N302C–I323C KQIINMWQEVGKAMYA–RPNNCTRKSIHIGPGRAFYTTGECG
C4–V3 N301C–G325C KQIINMWQEVGKAMYA–RPNCNTRKSIHIGPGRAFYTTGEIIC
Peptides used for ELISA
V3L Biotin- GSGTRKSIHIGPGRAFYTTGEI
V3 K305C–T320C Biotin- GSGTRCSIHIGPGRAFYTCGEI
V3 K305C–G321C Biotin- GSGTRCSIHIGPGRAFYTTCEI
V3 R304C–G321C Biotin- GSGCKSIHIGPGRAFYTTC
V3 T303C–E322C Biotin- SGSCRKSIHIGPGRAFYTTGC
V3 T303C–I323C Biotin- GSGCRKSIHIGPGRAFYTTGEC
V3N302C–I323C Biotin- GSGCTRKSIHIGPGRAFYTTGECG
V3 N301C–G325C Biotin- GSGCNTRKSIHIGPGRAFYTTGEIIC
C4 Biotin- GSGKQIINMWQEVGKAMYA
a Peptides are referred to by the residues that were replaced by cysteines; residues
replaced by cysteines are underlined.
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Therefore, the conserved structural and sequence motifs in the V3 loop
could be used, in principle, to induce a broadly neutralizing immune
response. Indeed, this is consistent with recent data suggesting that a
V3-directed antibody response both in infected patients and following
vaccination can be more broadly reactive than initially assumed (Davis
et al., 2009b). However, inmost primary isolates theV3 is concealed and
as a result these strains are resistant to V3-directed antibodies.
Linear V3 peptides can in principle be used as a component of an
anti-HIV-1 vaccine (Haynes et al., 2006). However, such peptides, and
even peptides representing the entire 35-residues V3 region with its
native disulﬁde bond at its base, are mostly ﬂexible in solution and
except for a transient β-turn formed by the GPGR segment do not
have a well-deﬁned secondary structure (Chandrasekhar et al., 1991;
Mor et al., 2009; Zvi et al., 1992). As a result of this ﬂexibility,
unconstrained V3 peptides used as immunogens likely induce a broad
distribution of antibodies, many of whichwill not recognize the native
conformation of the corresponding region in gp120. Nevertheless, in a
very comprehensive study Haynes et al. (2006) demonstrated
neutralization of a spectrum of neutralization sensitive HIV-1 isolates
by immune sera obtained after immunization with a panel of 29 linear
V3 peptides in the form of C4–V3 peptides.
Many attempts have been made to constrain the V3 structure using
backbone cyclization and disulﬁde bond constraints. These focused
mostly on short segments centered at the GPGR sequence (Cabezas et
al., 2000; Tolman et al., 1993) or used sequences from HIVIIIB or HIVMN
laboratory adapted X4 strains containing 8 to 23 residues (Conley et al.,
1994). Signiﬁcantly, the anti-sera were primarily selective for neutral-
ization of the strainharboring the immunogenic sequence andexhibited
weak to moderate HIV-1 neutralization. Anti-sera obtained after
immunization with a 23-residue disulﬁde-cyclized V3MN peptide
neutralized also AL-1, SF-2 and HIVIIIB at higher concentrations but not
four other strains that were tested. Shorter disulﬁde constrained
peptides were less effective immunogens. Later attempts to use V3
peptides constrained with a hydrazone link for immunization (Cabezas
et al., 2000) yielded considerably poorer neutralization results in
comparison with the experiments of Conley et al. (1994).
A number of laboratories have created V3-immunogens by inserting
short V3 segment, centered on the GPGR sequence, into loops of proteins
(Bryder et al., 1999; FitzGerald et al., 1998; Fontenot et al., 1995). In some
casesmoderate levels ofV3directedantibodiesweregeneratedandweak
cross-clade neutralization was observed (Chakraborty et al., 2006).
Stabilization of a β-hairpin conformation in the chimeric protein by
introducing a disulﬁde bond connecting residues 307 and 318 resulted in
a decrease in V3-speciﬁc antibody levels and loss of neutralization
(Chakraborty et al., 2006). Amore successful recent study used the entire
V3, with the native disulﬁde bond at its base, fused to a carrier protein, to
immunize rabbits (Zolla-Pazner et al., 2008). Cross-clade HIV-1 neutral-
ization has been demonstrated using a clade-C gp120 DNA prime with a
boost of a fusionprotein containing theentire 35 residue clade-B cyclicV3
(Zolla-Pazner et al., 2009). Thus although mixed results have been
reported, it is clear that properly designed constrained V3 antigens can
lead to a potent HIV-1 neutralizing antibody response.
Inprevious studiesweuseddisulﬁdebonds to constrain theV3 to the
conformation recognized by the 447-52D antibody (Mor et al., 2009).
We showed that some of the constrained peptides exhibited higher
afﬁnity to 447-52D Fab in comparison with linear V3 peptides (Mester
et al., 2009). In the present communication, we report on a series of
immunogens designed using the previous NMR and biochemical data.
The constrained V3 peptides were linked to an 18-residue segment of
the gp120 C4 region, which is known to be a helper T-cell epitope
(Haynes et al., 2006; Sha et al., 2004; Zinckgraf et al., 1999) and is
required in order to elicit a robust antibody response. The C4–V3
peptideswere synthesized by solid phase approaches, cyclized andused
to immunize rabbits. Our results clearly show that a constrained V3
peptide can elicit a more potent HIV-1 neutralizing response incomparison with a linear peptide and gp120 immunogens. However,
the location of the disulﬁde bond must be chosen carefully.Results
Design and synthesis of disulﬁde-constrained V3-peptide immunogens
The constrained peptides used as immunogens in the present study
were based on the consensus sequence for clade-B R5 viruses and
included theentire epitope recognized by the 447-52Dantibody (K305–
T320) (Table 1) with seven additional residues at the N-terminus
(298RPNNNTR304) and twoor four residues at theC-terminus (322EI323 or
322EIIC325, respectively ). The elongation of the sequence added residues
T303 and R304 that were found to interact extensively with 2219
(Stanﬁeld et al., 2006). R304 and K305 have been found to be critical for
the interactions of several HIV-1 neutralizing antibodies with V3
(Pantophlet et al., 2008) and therefore it was important to include
them in our immunogen design. To constrain a peptide to the 447-52D-
bound conformations of V3, a disulﬁde bond could be inserted at
positions 301, 303, 305 or 307 of the N-terminal strand of the V3 loop
(Mester et al., 2009; Mor et al., 2009). Residue I307 is part of the V3
epitope recognized by 447-52D, and interacts extensively with this
antibody (Sharon et al., 2003). Therefore, its replacement could be
detrimental to obtaining antibodies cross-reactive with native gp120.
Moreover, a disulﬁde bond involving residue 307 (and either 318 or 319
in the C-terminus) would not constrain N-terminal residues found
upstream of 307 (i.e. 305 and 306), and C-terminal residues found
downstream of 318/319 (i.e. 319 and 320) to a β-hairpin conformation
(Mor et al., 2009). We therefore decided to test peptides constrained
using disulﬁde bonds involving residues 301, 303 or 305. The peptides
constrained at positions 303 and 305 bound more strongly to 447-52D
in comparisonwith the linear V3 peptideswith V3K305C–T320C exhibiting
the highest afﬁnity to 447-52D (Mester et al., 2009). The peptides were
designed to mimic the conformation of either V3MN or the V3consensus
bound to 447-52Dwhichdiffer in thepairing of the residues in theV3β-
hairpin (Mester et al., 2009; Mor et al., 2009; Rosen et al., 2006; Sharon
et al., 2003). Furthermore two additional V3 peptides were designed to
mimic the conformation of V3IIIB bound to the 0.5β antibody. This
antibody is a strain speciﬁc antibody and V3 peptides constrained to the
0.5β-bound conformation exhibited a signiﬁcant reduction in afﬁnity to
447-52D antibody (Mester et al., 2009).
The 0.5β-bound V3 conformation is different from that of the 447-
52D-bound conformation in the hydrogen bond forming residues in the
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bound conformation a disulﬁde bond could be inserted at positions 302,
304 or 306 of the V3 loop (Mester et al., 2009; Mor et al., 2009). In this
study we included two V3 peptides constrained to the above
conformation using a single disulﬁde bond involving replacement of
either N302 or R304 by cysteine (i.e. C4–V3N302C–I323C and C4–
V3R304C–G321C respectively) (Table 1). The immunogens used in this
investigation contained 40 or 42 residues and regions with a signiﬁcant
tendency to assume β-sheet structures. β-Sheet formation during solid
phase peptide synthesis often buries the chain ends and prevents chain
elongation. Although all peptides were synthesized using automated
solid phase peptide synthesizer with double coupling and capping after
each step, the ﬁnal crude product had signiﬁcant heterogeneity
(Fig. 1A). Moreover, in several syntheses we originally failed due to
the early termination of the chain assembly. Truncation sequences
formed in these syntheses were identiﬁed by mass spectrometry and
the difﬁcult couplings were circumvented by changing the coupling
conditions or lowering the substitution on the resin to eliminate
intermolecular interactions of growing peptide chains. Despite the
synthetic challenges, using ESI MS we were able to identify the linear
disulfhydryl precursor product and using preparative reversed phaseFig. 1. Chromatographic and Mass-Spectra (MS) evaluation of synthetic constrained immun
(C) C4–V3 N301C–G325C. ESI-MS spectrum of puriﬁed linear (D) and puriﬁed cyclic (E) C4–V
0.1% TFA) over 20 min. Column: Zorbax-Eclipse XDB-C8, 150×4.6 mm. Flow-rate: 1.0 ml/m
linear was 4798.1 while the average molecular weight of the cyclic was 4796.0.HPLC we puriﬁed this to N90% homogeneity (Fig. 1B). The linear
sulfhydryl containing C4–V3 peptides or their biotinylated homologs
were oxidized to form the constrained immunogens using a variety of
procedures (see experimental procedures). No change in retention was
discerned on reversedphaseHPLCand the cyclizationwasmonitored by
mass spectrometry. In all cases, the ﬁnal cyclic peptide was highly
homogeneous (Fig. 1C and E; notice a 2 Da difference in mass between
Fig. 1D and E). The degree of cyclization was also ascertained by slowly
scanning the M/Z peaks and monitoring the isotope distribution (data
not shown). The MS results allowed us to distinguish small amounts of
linear peptide in the cyclic product. All peptides used in binding or
neutralization studies were N95% cyclic.
Reactivity of the C4–V3 immune sera with V3 and C4 peptides
A list of the constrained peptides used for immunization is
presented in Table 1. For comparison we tested also a gp120 and a
linear C4–V3 immunogen. Initially rabbits immunized with C4–V3L,
C4–V3T303C–I323C and C4–V3K305C–T320C were subjected to a 4th and a
5th inoculation at weeks 13 and 37, respectively. The post-4 sera
displayed a small reduction in binding titer to the corresponding V3ogens. Analytical HPLC proﬁle of crude linear (A), puriﬁed linear (B) and puriﬁed cyclic
3N301C–G325C. The HPLCwas run using a 10–60% acetonitrile/water gradient (containing
in. Detection at 220 nm. Product Rt 11.799 min. The average molecular weight of the
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in order to follow the V3 titer also indicated some reduction in
antibody levels. The animals were rested and injected for the ﬁfth
time at week 37. Serum drawn after the 5th inoculation had lower
levels of V3 antibodies than post-3 sera (data not shown). Therefore,
sera drawn after the 3rd inoculation were considered optimal, and
tested for gp120 binding and neutralization of HIV-1 clade B viral
strains, and three injections were adopted as the standard protocol for
all further immunizations. High levels of V3 speciﬁc antibodies were
observed following three injections for all C4–V3 immune sera, with
geometric-mean-titer (GMT) values for half-maximal binding to the
homologous V3 peptides ranging from 3100 to 20000 (Table 2 and
Fig. 2) with the exception of C4–V3R304C–G321C, mimicking the 0.5β-
bound conformation, which elicited unusually low titers of anti-V3
antibodies (half-max GMT=1000). The highest titers were obtained
for C4–V3N301C–G325C and C4–V3T303C–E322C. To verify that most of the
antibody response was directed against the V3 epitope, the reactivity
of several of the sera was tested for V3 and C4 separately. Signiﬁcantly
lower C4 binding titers were observed compared with V3 titers
ranging from 150 to 1900. This reﬂects in most cases a 4 to 30 foldTable 2
Summary of binding data obtained by ELISAa.
Rabbit Immunogen V3 gp120 C4
B712 C4–V3L 1800 660 420
B707 C4–V3L 1800 840 150
B702 C4–V3L 12500 7700 ND
B722 C4–V3L 4200 2900 ND
GMT 3600 1880
B717 C4–V3K305C–T320C 8300 8300 1400
B715 C4–V3K305C–T320C 2400 1400 220
B719 C4–V3K305C–T320C 11000 7700 ND
B723 C4–V3K305C–T320C 4300 2000 ND
GMT 5500 3700
B866 C4–V3K305C–G321C 4350 4000
B871 C4–V3K305C–G321C 1600 1600
B872 C4–V3K305C–G321C 2400 1500
B873 C4–V3K305C–G321C 5300 3300
GMT 3100 2400
B961 C4–V3T303C–E322C 20000 25000 1500
B962 C4–V3T303C–E322C 10000 10000 330
B963 C4–V3T303C–E322C 14000 14000 850
B964 C4–V3T303C–E322C 50000 50000 1700
GMT 19000 20000
B966 C4–V3R304C–G321C 510 820 312
B967 C4–V3R304C–G321C 1200 1500 450
B968 C4–V3R304C–G321C 660 690 317
B975 C4–V3R304C–G321C 2700 2300 549
GMT 1000 1200
B716 C4–V3T303C–I323C 2400 2800 260
B720 C4–V3T303C–I323C 6250 7700 460
B714 C4–V3T303C–I323C 5900 5000 ND
B718 C4–V3T303C–I323C 12500 14000 ND
GMT 5800 6200
C018 C4–V3N302C–I323C 12500 12500
C020 C4–V3N302C–I323C 3300 2300
C022 C4–V3N302C–I323C 5300 4200
C024 C4–V3N302C–I323C 17000 17000
GMT 7800 6700
B889 C4–V3N301C–G325C 50000 50000 1900
B890 C4–V3N301C–G325C 11000 8300 960
B892 C4–V3N301C–G325C 14000 10000 1300
GMT 20000 16000
B955 gp120 5900 17000
B958 gp120 3700 12500
B959 gp120 2700 14000
B960 gp120 * *
GMT 3900 14000
a Binding of the C4–V3 and gp120 elicited immune sera to V3 peptides, gp120 and
the C4 peptide. Immune-sera were obtained after three immunizations and half-
maximal values of the binding reaction were determined. ND—not determined.
Geometric mean titer (GMT) is presented. * Undetectable levels of binding (excluded
from calculation). Values are rounded to two signiﬁcant ﬁgures.reduction in the C4 titer in comparison with the V3-titer with the
exception of C4–V3R304C–G321C which elicited low V3 titers (Table 2).
Cross-reactivity of the C4–V3 immune sera with gp120
An essential prerequisite for neutralization by vaccine-elicited sera is
that it will be cross-reactive with a gp120 protein in which the V3 is
exposed. Therefore, the pre-immune and the immune sera were tested
for binding to the ΔV1/V2 gp120 construct in which the V3 is fully
exposed(Fig. 3, Table2)bya simpleELISA test. For each serumthe relative
binding to the corresponding V3 peptide and gp120 molecule was
calculated and the data is presented as the average of the ratio between
gp120 and the immunizing-peptide binding (Fig. 3). The two peptides
constrained by a disulﬁde bond involving residue 303 elicited sera that
bound gp120 as strongly as they bound the V3-peptide immunogen,
while the sera from the rabbits immunized with the linear V3 (V3L)
peptidewas the least cross reactive to gp120with an average ratio of 0.54
(p=0.0078) between gp120 and V3L binding (Fig. 3). The average ratios
betweengp120 and constrainedV3peptide bindingof the serum induced
byC4–V3K305C–T320C andC4–V3K305C–G321C,whichwere constrained to the
V3MN (Sharon et al., 2003) and V3consensus conformation (Rosen et al.,
2006), respectively, were 0.69 and 0.79, respectively, while the sera
elicited by C4–V3N301C–G325C had a ratio of gp120/constrained V3 peptide
bindingof0.82. For these last threepeptides the reducedbinding togp120
was less consistent than for the linear peptide as evidenced by the larger
standard deviation which did not reach statistical signiﬁcance as judged
by the T-test (P value ranging from 0.07 to 0.19).
Of the two peptides designed to mimic the 0.5β-bound V3-
conformation C4–V3N302C–I323C had a small reduction in afﬁnity to
gp120 compared with it homologous V3 peptide, and C4–
V3R304C–G321C unexpectedly had a little higher afﬁnity to gp120 than
to its homologue V3 peptide. For both peptides this observation was
not statistically signiﬁcant (P value of 0.193 and 0.327 respectively).
Due to the low V3 titer in this later peptide we believe that this
observation is not signiﬁcant. Thus, although the differences in gp120
cross-reactivity among the different peptides' immune-sera are not
large, it is clear that peptides constrained by a disulﬁde bond involving
residue 303 to the conformation of the V3 bound to 447-52D
exhibited higher cross-reactivity with gp120 in comparison with the
sera elicited by the ﬂexible linear peptide and the other C4–V3
peptides in which the V3 was constrained to the conformations
recognized by the 447-52D antibody.
The reactivity of the peptide immune-sera is conformation dependent
To further characterize the conformational speciﬁcity of the immune
serawe tested the binding of the C4–V3L andC4–V3T303C–I323C immune-
sera to the V3T303C–I323C peptide in a reduced and cyclic form and as a
control we tested binding to V3L in the presence and absence of
reducing agent (Fig. 4). For the C4–V3L immune sera, the ratio between
cyclic V3T303C–I323C binding and V3L binding was 0.64 and the ratio
between reducedV3T303C–I323C andV3Lbindingwas0.89, indicating that
most of the decrease in the binding of the C4–V3L immune sera to cyclic
V3T303C–I323C compared with the V3L peptide is due to the disulﬁde-
bond constraint (P=0.0004 for reduced vs. cyclic). The ratio between
C4–V3T303C–I323C immune-sera binding to cyclic V3T303C–I323C and V3L
was 1.16 while the ratio between reduced C4–V3T303C–I323C and V3L
binding was 0.97 (P=0.0083 for reduced vs. cyclic). These results
indicate that the C4–V3T303C–I323C immune sera bind slightly better to
the peptide constrained by a disulﬁde bond implying recognition of the
conformation of this epitope. Moreover only a fraction of the C4–V3L
immune sera bound gp120 and constrained V3T303C–I323C (Figs. 3 and4).
The reduced reactivity of the C4–V3L induced sera with the cyclic
V3T303C–I323C compared to the reduced V3T303C–I323C indicated that these
immune sera elicited an antibody response that recognized a wider
range of conformations than those represented by V3T303C–I323C.
Fig. 2. Binding of antibodies elicited by C4–V3 peptides or gp120 to the corresponding V3 peptide and gp120. A) Rabbit B707 serum, immunized with C4–V3L, B) Rabbit B963 serum,
immunized with C4–V3T303C–E322C, C) Rabbit B892 immunized with C4–V3N301C–G325C and D) Rabbit B959 serum, immunized with gp120. Binding to the homologous peptide is
shown in triangles (▲ post-immune, Δ pre-immune). Binding to gp120 in is shown in squares (■ post-immune,□ pre-immune). Y-axis represents OD at 650 nm; X-axis represents
the reciprocal of serum dilution. Standard deviation is for duplicates on plate.
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We compared the immune response against the C4–V3 peptide
immunogens with that obtained against gp120 to determine whether
there is anyadvantage inusing constrainedV3peptides toobtainapotentFig. 3. Relative cross reactivity of immune sera with gp120 and V3 peptide
immunogens. The ratio between the immune-sera binding to gp120 and binding to
the homologous peptide used for immunization is represented. The ratio is obtained by
dividing the half maximal titer for gp120 by the half maximal titer to the V3 peptide
used as immunogen. Shown is the average and standard deviation for each of the four
rabbits immunized with each of the peptides. Peptide immunogens are listed by the
positions replaced by cysteine according to Table 1. P-value for one sample T-test for a
hypothetical mean of 1 is shown above the histograms.HIV-1 neutralizing response. The gp120 construct used as immunogen in
this study contained the full length V3 loop, lacked the ﬁrst and second
variable loops as well as the ﬁrst 86 and last 19 N- and C-terminal
residues, respectively, and was homogenously glycosylated with Man5-
GlcNAc2 glycans at sites normally occupied by complex or hybrid glycans
(seeMaterials andmethods). Three out of the four rabbits raised a strong
anti-gp120 immune response; however one rabbit had undetectable
antibody levels against both gp120 and V3 (B960) and therefore was
excluded from the GMT calculation and from the analysis (Table 2). TheFig. 4. Inﬂuence of peptide conformation on the binding of immune sera to a cyclic V3
peptide. The binding of the immune-sera to cyclic vs. reduced V3T303C–I323C is compared
to binding to V3L for the C4–V3L and C4–V3T303C–I323C induced sera. Half-maximal
binding titer to cyclic and reduced V3T303C–I323C and to V3L with and without DTT was
determined by ELISA for each V3T303C–I323C and V3L immune serum. In each experiment
the binding of the serum to V3T303C–I323C in the cyclic (dark) or reduced state (light)
was divided by the binding to V3L. Shown is the average and standard deviation for
each of the four rabbit immune sera. P-value for two samples T-test for reduced vs.
cyclic is shown.
Table 3
V3 sequence of the viral strains tested for neutralization by the immune seraa.
Strain Tropism V3 sequence
JR-FL R5 TRKSIHI–GPGRAFYTTGEII
SF-162 R5 .....T.–.......A..D..
MN X4 K..R...–.........KN..
NSC R5 ..R..TM–.............
BX08 R5 .......–..........D..
Bal R5 .......–.............
SS1196 R5 .......–..........GV.
6535 R5 .....NL–..........D..
QH0692 R5 .......–..........D..
JR-CSF R5 .......–.............
NL-43 X4 .....R.QR......V.I.K-.
a V3 sequence (residues 303–324) of viral strains compared to JR-FL representing the
clade-B consensuses, · identical to consensuses; - (deletion).
Table 4
Neutralization of clade-B isolates by the C4–V3 and gp120 immune seraa.
a Titers, calculated as the serum dilution conferring 50% inhibition (IC50) of pseudovirus in
by consecutive two-fold dilutions. Highlighted in gray are samples in which the IC50 was at
(GMT) is presented (b10 was calculated as 10). N.D=not determined. N.N=non-neutraliz
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was 14,000. This was comparable to the GMT values measured for
binding to the homologous V3 immunogen of immune sera from
constrained V3 peptides that elicited strong antibody responses such as
C4–V3N301C–G325C and C4–V3T303C–E322C. The V3 directed antibody
responses of the gp120-immune sera, as measured by V3T303C–I323C
binding, were 2.8 to 5.3 fold lower than that against gp120, with GMT for
half-maximum binding of 3900. The peptide V3T303C–I323C was used in
this experiment to assess the V3-directed response of the gp120
immune-sera because a very good correlation between gp120 and
peptide binding was observed for the sera elicited by this peptide (see
above). The results indicate that gp120 elicited an antibody response to
other epitopes in addition to the V3 crown (residues R304–E322), and
that a moderate level of V3 directed antibodies was obtained using the
gp120 construct in which the V3 loop is fully exposed by deletion of thefection are presented. The ﬁrst measurement was done at 1:10 dilution andwas followed
least 3× higher than any inhibition of the aMLV negative control. Geometric mean titer
ing. * excluded from calculation due to lack of immune response in that rabbit.
Fig. 5. Comparison of the neutralization of SF-162. GMT for serum dilution inﬂicting 50% inhibition (IC50) of SF-162 is presented for the different immunogens used in the study.
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the protein.
Neutralization of clade-B neutralization sensitive HIV-1 isolates by C4–V3
and gp120 immune sera
A pseudovirus based neutralization assay was used to evaluate the
potency and breadth of the neutralizing antibody response elicited by the
different C4–V3 and gp120 immunogens against a spectrum of clade-B
viruses. Initially we focused on strains that are highly sensitive to
neutralization. All serawere tested against Bal, BX08,MN, SF-162 andNL-
43 strains and all sera except C4–V3K305C–G321C were tested also against
NSC. JR-CSF, which is known to be a neutralization resistant strain, was
also included in all the tests. The V3 sequences and phenotype of these
HIV-1 strains are presented in Table 3. All strains are R5 viruses with the
exception of MN and NL-43 which utilize CXCR4. aMLV (Murine
Leukemia Virus) was used as a negative control. As a further control,
representative pre-immune sera were tested for neutralization of SF-162
and no neutralization activity was detected (data not shown). The
neutralization results are summarized in Table 4. The most effective
immunogens were peptides constrained at position 303, of which C4–
V3T303C–E322C, representing the conformation of a V3MN peptide bound to
447-52D, induced the strongest neutralizing response demonstrated by
the effective neutralization of SF-162 (Fig. 5). Both C4–V3T303C–E322C and
C4–V3T303C–I323C immune sera neutralized the four R5 neutralization
sensitive strains as well as MN which is an X4 strain. C4–V3T303C–E322C
immuneseraneutralizedalso theX4neutralization-sensitive strainNL-43
and thesewere theonly immunesera thatneutralizedNL-43signiﬁcantly.
It should be noted that NL-43 contains a rare two residue insertion
preceding the GPGR segment in the V3 loop. Importantly, both peptides
induced amuchmore potent neutralizing response then the linear C4–V3
peptide. Only one linear-peptide immune-serum neutralized ﬁve
sensitive strains and two other C4–V3L immune-sera neutralized only
the two most neutralization sensitive strains, SF162 and NSC. The
neutralization titers were on average signiﬁcantly lower for C4–V3L
immune sera than those elicited by peptide immunogens constrained at
T303. For example, the IC50 GMT of C4–V3L immune sera for NSC
neutralization was more than one order of magnitude lower than that of
the C4–V3T303C–I323C immune sera and two orders of magnitude lower
than that of C4–V3T303C–E322C immune sera. Peptides constrained at K305
were found to be even less effective than the linear peptide in inducing
antibodies capable of neutralizing HIV-1 isolates; none of the sera in the
two groups of rabbits immunized by these peptides neutralized all
sensitive strains tested, only one serum in each group neutralized more
than two strains and the neutralization titers were much lower in most
cases than those observed for the other constrained C4–V3 peptides. Thepeptide C4–V3N301C–G325C is constrained to assume the same V3consensus
conformation as C4–V3T303C–I323C. However, its disulﬁde bond is removed
further away from the GPGR loop and the ring size enclosed by the
disulﬁdebond is therefore four-residues larger. This peptidewas included
in order to test whether T303 is the optimal position for the disulﬁde
constraint. C4–V3N301C–G325C induced a potent anti-gp120 and anti-V3
response which was more effective than that elicited by either the linear
peptide or the peptides constrained at K305, nevertheless it was not as
potent as C4–V3T303C–I323C and C4–V3T303C–E322C in eliciting an HIV-1
neutralizing response. For example, the IC90 GMT for SF-162 is two and
three-fold higher for the C4–V3T303C–I323C and C4–V3T303C–E322C immune
sera in comparisonwith the C4–V3N301C–G325C immune sera. Only one out
of three immune sera reached 90% inhibition for MN in the group
immunized with C4–V3N301C–G325C compared with three out of four and
four out of four for C4–V3T303C–I323C and C4–V3T303C–E322C immune sera,
respectively (data not shown). This demonstrates that T303 is indeed the
optimal position for the disulﬁde bondwhenV3 peptides are constrained
to the 447-52D-bound conformations. The modiﬁed gp120 molecule
elicited a relatively modest neutralizing response that resembles the
antibody response elicited by C4–V3N301C–G325C and although it neutral-
ized the two most sensitive strains only one serum neutralized all ﬁve
sensitive strains that we tested.
Both peptides designed to mimic the 0.5β-bound conformation
elicited poorneutralizing responses (Table 4 and Fig. 5). Noneof theC4–
V3N302C–I323C induced sera neutralized all ﬁve sensitive strains and only
two sera neutralized more than one strain. These results demonstrate a
drastic decline in neutralization potency compared with the immune
sera of peptides constrained to the 447-52D conformation at positions
303 or 301. C4–V3R304C–G321C elicited an even poorer neutralizing
response with only two sera capable of neutralizing SF-162. Due to the
low V3 titer in C4–V3R304C–G321C this group of rabbits was subjected to
two additional boosts. Two to three-fold higher V3 titer was detected
after the ﬁfth inoculation and improved neutralization titers were also
achieved with IC50 GMT of 630 and 111 (for 3/4 available) for SF-162
and MN, respectively). Nevertheless the neutralization was limited to
SF-162 andMN. None of the sera neutralized BX08 and only one serum
neutralized Bal (data not shown).
Altogether our results support the use of peptides based
immunogens over gp120 based immunogens and demonstrate the
beneﬁt of optimally constraining the V3 loop to induce a more potent
and cross-reactive neutralizing response.
Neutralization of clade-B moderately resistant HIV-1 primary isolates
In order to further assess the neutralizing potential of the immune
sera, the sera for C4–V3L, C4–V3T303C–E322C, C4–V3T303C–I323C and
Table 5
Neutralization of clade-B modestly resistant strainsa.
a Titers, calculated as the plasma dilution conferring 50% inhibition (IC50) are shown.
Geometric mean titer (GMT) is presented (b10 was calculated as 10). Highlighted in gray
are samples in which the IC50 was at least 3× higher than any inhibition of the aMLV
negative control. N.N=non-neutralizing. * excluded from calculation due to lack of
immune response in that rabbit.
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6535 and QH0692. As shown in Table 5 no neutralization of these
strains was detected for the C4–V3T303C–I323C, and gp120 sera and only
one serum from rabbits immunized with C4–V3L weakly neutralized
SS1196. However, C4–V3T303C–E322C immune sera were able to
neutralize SS1196 with GMT of 64 (average of 4/4 rabbits), and
6535 with GMT of less than 26 (37 when average is calculated for 3
out 4 rabbits that showed neutralization) but not QH0692 which is
more difﬁcult to neutralize in comparison with 6535. This experiment
clearly demonstrates that C4–V3T303C–E322C immune sera can neutral-
ize several primary isolates that are more resistant to neutralization
and the immunogenic potential of properly constrained V3-peptides
over linear peptides and monomeric-gp120 based constructs.
Discussion
This study evaluated the hypothesis that antibodies elicited by V3
peptides constrained to a conformation that mimics the β-hairpin
conformation of the V3 loop will be more cross-reactive with
monomeric gp120 and more potent in neutralizing HIV-1 compared
with anti-sera elicited by the homologous linear V3 peptide. To test
this hypothesis we used structural data acquired on constrained V3
peptides (Mor et al., 2009) together with the 447-52D binding afﬁnity
of these peptides to guide the design of V3 peptide immunogens
constrained by a single disulﬁde bond. Our design considered the
hydrogen bond network and the cross-strand alignment of the β-
hairpin conformation observed in the NMR structures of V3 peptides
bound to antibody 447-52D (Rosen et al., 2006). Based on the above
we systematically changed the location of the disulﬁde bond and
compared the gp120 cross reactivity and HIV-1 neutralizing response
obtained by immunization with the constrained-peptide to that
obtained by an analogous linear V3-immunogen and by monomeric-
gp120. This analysis has lead to the following observations.
Peptides constrained by a disulﬁde bond involving residue 303 were
more effective immunogens for eliciting sera with gp120 cross-reactivity
Of the peptide mimicking the 447-52D conformation, C4–
V3T303C–E322C and C4–V3T303C–I323C induced immune sera showed thebest cross-reactivity with monomeric-gp120 in comparison with C4–
V3L with ratios of 1.06 and 1.1 between binding to gp120 and the
corresponding V3 peptide, respectively (Fig. 3). These values indicate
that the immune sera recognize monomeric-gp120 as well as they
recognize the V3 immunogen. The C4–V3K305C–T320C and C4–
V3K305C–G321C immune sera exhibited slightly poorer cross-reactivity
with gp120 (ratios of 0.69 and 0.79, respectively). This is despite the fact
that the afﬁnity to 447-52D of V3K305C–T320C is slightly higher than that
of V3T303C–E322C and the afﬁnity of V3K305C–G321C is higher than that of
V3T303C–I323C (Mester et al., 2009). Unlike 447-52D which is tolerant to
replacements of amino acids in the β-strand (Keller et al., 1993;
Stanﬁeld et al., 2004), and to replacements of K305 and I307 by cystine
(Mester et al., 2009) it is possible that a subpopulation of the antibodies
elicited by V3K305C–T320C and V3K305C–G321C interact with the side chain
of the cystine residueatposition305andare sensitive to its replacement
by other residues.
The immune sera of peptides constrained to the 0.5β-bound
conformation cross-reacted very well with monomeric-gp120. C4–
V3N302C–I323C immune sera had a small reduction in binding to gp120,
and C4–V3R304C–G321C immune sera had a slightly higher antibody titer
to gp120 than to its homologous V3 peptide. Nevertheless C4–
V3R304C–G321C was a poor immunogen inducing low V3 peptide
antibody titers (GMT 3–20 fold lower compared with other peptides),
that are comparable to the C4-directed antibody titer. Due to the
ﬂexible nature of the gp120 used we cannot exclude the possibility
that C4 binding played a role in the slight increase in gp120 binding
compared with the V3 titer. Notably, several studies have demon-
strated that antibodies raised against linear C4 peptide have limited
gp120 binding and no neutralization activity (Kelker et al., 2010;
Robey et al., 1995). Therefore, the observation of C4-binding anti-
bodies is not relevant for neutralization.
The linear C4–V3L peptide elicited antibodies that were less cross-
reactive withmonomeric-gp120 in comparisonwith the V3T303C–E322C
or V3T303C–I323C immune sera. Nevertheless the signiﬁcant cross-
reactivity of the C4–V3L immune sera with gp120 is surprising
(binding ratio gp120/V3L=0.54). This ratio is only a factor of two
lower than that observed for the immune-sera of peptides con-
strained by a disulﬁde bond involving residue 303. It is known that the
GPGR segment in V3 peptides transiently populates a β-turn
conformation (Chandrasekhar et al., 1991; Zvi et al., 1992). Thus,
although it does not form a β-hairpin like conformation, the V3L
peptide is not completely ﬂexible. The β-turn forming GPGR segment
is the core epitope for many V3-directed HIV-1 neutralizing
antibodies and, for example, in the V3MN complex with 447-52D the
GPGR segment occupies a central pocket in the antibody binding site.
The signiﬁcantly populated β-turn conformation of V3L, a conforma-
tion that most likely characterizes the corresponding region in native
gp120, may be the reason why this peptide elicits a relatively high
proportion of gp120-cross-reactive antibodies which neutralize HIV-1.
In this study the monomeric gp120 immunogen was designed to
present an exposed V3 in order to gain data about the reactivity of the
sera with V3-containing gp120 without the effect of epitope masking,
Themost signiﬁcantﬁndingwas the relatively low cross reactivity of the
linear peptide compared with other constrained peptides and that
peptides constrained at T303 are the most potent immunogens. The
conclusion that the T303 constrained-V3 peptides are viable immuno-
gens is supported by the neutralization of different HIV-1 strains with
different levels of V3 masking by sera raised against C4–V3T303C–I322C.
Peptides constrained to mimic the 0.5β-bound conformation elicited
considerably poorer HIV-1 neutralizing responses compared with
peptides mimicking the 447-52D-bound conformation
In this study we focused on identifying the most effective disulﬁde
constrained V3 peptide, using the 447-52D-bound conformation of the
V3 as a template for constraining V3 peptide immunogens. Additionally
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V3. Our data clearly shows that V3 peptides constrained to the 0.5β-
bound conformation resulted in serawhichexhibited adrastic decline in
HIV-1 neutralizing capability. Even C4–V3N302C–I323C which retains the
entire 447-52D epitope unchanged, elicited signiﬁcantly poorer
neutralization responses compared with C4–V3T303C–I323C C4–
V3T303C–E322C and C4–V3N301C–G325C. This observation indicates that
the hydrogen-bond network and the resulting side-chain conformation
govern the nature of the elicited antibody response. C4–V3R304C–G321C
elicited low levels of V3 directed antibodies and only sporadic HIV-1
neutralizing responses. Taken together the comparison of sera raised
against peptides constrained to mimic 0.5β- and 447-52D-bound V3
conformations clearly shows that the 447-52D-bound conformation is
indeed a useful model for designing peptide immunogens that elicit an
HIV-1 neutralizing antibody response.
Apeptide constrained bya disulﬁdebond linking residues 303and322 is the
most effective V3 immunogen for eliciting an HIV-1 neutralizing response
Comparison of the neutralization efﬁciency of a panel of HIV-1
strains by the immune sera elicited by the different peptide immuno-
gens reveals that the peptide V3T303C–E322C is optimally constrained and
that it elicited a considerably more potent HIV-1 neutralization in
comparison with the linear peptide and with peptides constrained by a
disulﬁde bond containing both shorter and longer ring sizes (i.e.
V3K305C–T320C, V3K305C–G321C and V3N301C–G325C). This was reﬂected in a
signiﬁcantly higher neutralizing titer when comparing neutralization
sensitive strains. For example, when neutralization of the neutraliza-
tion-sensitive strain SF162 was compared among the immune-sera
elicited by the different constrained-peptide immunogens, we found
that the neutralization efﬁciency of the C4–V3T303C–E322C sera was at
least 30-fold higher than that of C4–V3L immune sera, and more than
48-fold higher than the V3K305C–T320C, V3K305C–G321C immune sera
(Fig. 5). When the disulﬁde bond was located further away from the
GPGR segment, i.e. involving position 301 and 325, the neutralization
efﬁciency dropped bymore than three fold suggesting that position 303
is optimal for the disulﬁde bond location.
As shown in Table 5 C4–V3T303C–E322C immune sera were capable
of neutralizing SS1196 and 6535 primary isolates, of which 6535 is
considered difﬁcult to neutralize. These strains were not neutralized
by C4–V3T303C–I323C immune sera. This immunogen encloses a ring
that is only one residue longer than that of C4–V3T303C–E322C and that
has the same hydrogen forming network at the N-terminus. This
demonstrates the need to ﬁne tune the location of the disulﬁde bond
in order to achieve the most effective antibody response. Taken
together with its ability to neutralize NL-43 the neutralization of
strains SS1196 and 6535 indicated that C4–V3T303C–E322C elicited an
antibody response that is different than that of C4–V3T303C–I323C and
can neutralize a wider range of viral strains including those that are
more resistant to neutralization.
It is surprising that the C4–V3L, C4–V3K305C–T320C and C4–
V3K305C–G321C elicited much poorer HIV-1 neutralizing responses in
comparison with C4–V3T303C–E322C and C4–V3T303C–I323C although the
differences in gp120 cross-reactivity were not pronounced. A possible
explanation is that both C4–V3T303C–E322C and C4–V3T303C–I323C
elicited a larger fraction of the high-afﬁnity antibodies that are crucial
for HIV-1 neutralization. Another possibility is that binding to the
modiﬁed monomeric gp120 does not reﬂect exactly the binding to V3
on the virus and that it could be that C4–V3T303C–E322C elicits
antibodies that can better access the V3 region on the virus.
C4–V3T303C–E322C elicits a better HIV-1 neutralizing response than
monomeric-gp120
The HIV-1 neutralization elicited by monomeric-gp120 in the
present study is considerably poorer than that elicited by C4–V3T303C–E322C. When neutralization of SF-162 or NSC is compared,
the C4–V3T303C–E322C immune sera were 5-fold or 10-fold, respective-
ly more potent than the gp120 immune sera (Table 4 and Fig. 5), and
the gp120 induced sera did not neutralize NL-43 at all. The poorer
HIV-1 neutralization by the gp120 immune sera was obtained despite
the fact that the V3 region was fully exposed in the truncated gp120
construct used in the present study (Huang et al., 2005). Two
conclusions can be reached on the basis of the observed poorer
neutralization by the gp120 immune sera. First, the gp120 construct
used in this study which is expected to elicit enhanced V3 response in
comparison with gp120 containing the V1 and V2 loop as well as
longer carbohydrate chains was a poorer immunogen in comparison
with C4–V3T303C–E322C. Second, if gp120 elicited neutralizing anti-
bodies that targeted regions other than the V3, their potency in HIV-1
neutralization was substantially weaker in comparison with the C4–
V3T303C–E322C immune sera. This is an important conclusion in view of
the fact that monomeric gp120 immunogens were used in the Thai
vaccine trial (Rerks-Ngarm et al., 2009).
The C4–V3T303C–E322C immune sera are broadly neutralizing
The panel of the HIV-1 strains neutralized by C4–V3T303C–E322C
includes eight strains, some of which are considerably different in
sequence from the immunizing consensuses sequence (Table 3).
Variations are observed at position T303, K305, S306, H308, I309,
Y318, T319, G321 and E322. The NL-43 strain that resembles HIV-1IIIB
is the most distant from the immunizing peptide and in addition to
four mutations (H308R, Y318V, T320I and E322K) it contains a two
residue insertion (Q310–R311) and a one residue deletion (I323).
Interestingly 447-52D neutralizes NL-43 and IIIB very efﬁciently while
other broadly neutralizing V3 directed antibodies fail to do so (Binley
et al., 2004; Eda et al., 2006). This implies that C4–V3T303–E322C is the
most effective in inducing an 447-52D-like antibody response.
Altogether these differences in the V3 sequences of the tested HIV-1
strains and especially the large differences between the NL-43 strain
and the immunizing peptide indicate that the immune sera generated
by the C4–V3T303C–E322C peptide are highly cross-reactivewith clade-B
viruses which contain the GPGR motif and are capable of neutralizing
both X4 and R5 viruses.
Peptide C4–V3T303C–E322C is the most potent constrained V3 immunogen
studied to date
Previously, the most comprehensive and successful study using
constrained V3 peptides was carried out by Conley et al. (1994), and
despite more recent studies, the most potent HIV-1 neutralizing
response remained the one induced using a 23-residue V3MN peptide
cyclized by a disulﬁde bond at its termini (L-705,402 or V3N300C–T326C
according to our nomenclature). The neutralization titer for the MN
strain was 640 and that for IIIB (similar to NL43 tested in the present
study) was more than 15-fold lower. Three additional clade-B strains
were neutralized (AL-1, SF-2 and WMJ-2) while three others (Du
6587-5, Du 7887-7 and RF) were resistant to the anti-sera. Conley
et al. (1994) concluded that the anti-V3 response was comparable to
that obtained by gp120 immunogens. Shorter peptides either lacking
the entire epitope recognized by 447-52D or which were poor mimics
of the V3 β-hairpin conformation resulted in considerably weaker
HIV-1 neutralizing responses.
Similar to the optimal V3 peptide discovered in the present study,
the long V3MN peptide used by Conley et al., L-705,402, contained the
entire epitope recognized by 447-52D. The 25-residue disulﬁde
enclosed ring in L-705,402 is slightly longer than the 23-residue
ring of V3N301C–G325C which showed reduced efﬁciency in eliciting a
potent HIV-1 neutralizing response compared to the V3T303C–E322C
peptide (18-residue ring) which was found to be the optimal
immunogen in our investigation. However, compared to the L-705,402
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improved neutralization of HIV-1 strains that differed in their V3
sequence from the consensus clade-B immunizing peptide. In addition,
V3T303C–E322C elicited at least a four-fold stronger HIV-1 neutralizing
response in comparison with gp120 while the peptides containing
longer ring size V3N301C–G325C and 705,402 (V3MNN300C–T326C) elicited
HIV-1 neutralizing responses comparable to that induced by gp120
(present study and Conley). Thus it appears that V3T303C–E322C has the
optimal ring size. It is likely that this optimum reﬂects a compromise
between the requirement to present the entire 447-52D epitope
without any replacement to cysteine residues and to contain as short
a ring size as possible to bettermimic the β-hairpin conformation of the
V3.
It should be noted that direct comparison of our results with those
obtained by Haynes et al. (2006) and by Conley et al. (1994) is not
possible because of the different animals used for immunization,
different peptide immunogens and different neutralization assays.
Therefore, the goal of this study was to test the principle of using a
linear V3 immunogen in comparison with a constrained V3-
immunogen under the same conditions. We hypothesized that the
constrained peptide found to be optimal in Conley's study contained a
ring structure that was too long and too ﬂexible and therefore the
second goal of this study was to determine the optimal location of the
disulﬁde bond constrained within the V3. Our data support our
hypothesis because the strongest HIV-1 neutralizing response was
elicited by a constrained peptide that contained a shorter ring size
than that found in Conley's peptide. In addition we compared the sera
elicited by gp120 to that elicited by the C4–V3 peptide under the same
conditions and demonstrated that optimally constrained V3 peptide
elicit more potent HIV-1 neutralizing response in comparison with
monomeric gp120 molecule.Conclusions
In the present studywe used the structure of V3-peptides bound to
antibody 447-52D to guide the design of constrained immunogens.
We found that the C4–V3T303C–E322C immunogen elicited a potent
HIV-1 neutralizing response that was more efﬁcient in neutralization
of sensitive strains, more broadly neutralizing, and more capable of
neutralizing primary isolates that are difﬁcult to neutralize than
previously studied constrained V3-immunogens. Small changes in the
location of the disulﬁde bond were shown to have a signiﬁcant impact
on the nature of the antibody response. The results support our
working hypothesis that constrained V3-peptides can be better
immunogens than their linear V3-peptide homologs and gp120.
Comparison of the different constrained V3 immunogens in view
of their NMR structure (Mor et al., 2009) and their afﬁnity to 447-52D
(Mester et al., 2009) leads us to conclude that: a) In order to achieve
an effective neutralizing response, V3 peptides must be designed to
mimic the 447-52D-bound conformation of the V3 as opposed to the
0.5β-bound conformation. b) It is important to include the intact
K305–T320 segment of V3 without replacement to cysteine. c) High
afﬁnity binding to 447-52D can be misleading in selecting an optimal
immunogen (Mester et al., 2009). d) It may not be necessary to
achieve a rigid β-hairpin conformation in the peptide immunogen and
some ﬂexibility may be beneﬁcial for eliciting a strong HIV-1
neutralizing response. e) The ring enclosed by the disulﬁde bond
should be minimal while containing the entire 447-52D epitope to
avoid too much ﬂexibility.
Finally, the results suggest that a V3-directed antibody response
can neutralize a broad subset of primary isolates which will be limited
primarily by the occlusion of this epitope in primary isolates.
Strategies to expose the V3 loop, focus the antibody response on
exposed V3 segments and increase the titer of the elicited antibody
response should, therefore, be vigorously pursued.Materials and methods
Chain assembly and puriﬁcation of the linear (SH) containing C4–V3
peptides
The C4–V3 peptides were synthesized on a 443A peptide
synthesizer (Applied Biosystems) using 0.1 mM fast Fmoc chemistry.
Approximately 160 mg (0.1 mM) of preloaded Fmoc-Ile Wang resin
(0.6 mmol/g) or Fmoc-Cys(Trt) Wang resin (0.5 mmol/g) were used.
The ﬁrst 10 amino acids were attached using single coupling, the
remaining amino acids were assembled into the peptide chain using
double coupling. The unreacted amino group was capped with acetic
anhydride at the end of each coupling step. The resin weight gain was
about 90% of theoretical and peaks with expected m/z values were
observed in the mass spectrum of the crude peptide. The peptides
were cleaved from the resin using a water/TFA cocktail with
appropriate scavengers. In a representative procedure, to a vial
containing 220 mg of the resin was added a solution of water
(0.50 ml), phenol (500 mg), 1,2-ethanedithiol (0.25 ml), thioanisole
(0.50 ml), triisopropylsilane (0.10 ml) and triﬂuoroacetic acid (TFA;
10 ml) and the resulting mixture was stirred at 0 °C for 1 h and at
room temperature for 2 h. Resin was separated from solution by
ﬁltration and washed two times with TFA. The combined ﬁltrate was
concentrated on a rotary evaporator under vacuum at a temperature
below 30 °C and the resulting residue was treated with cold diethyl
ether (40 ml). Precipitated peptide was isolated by centrifugation and
ether was removed by decantation. After washing the solid precipitate
was dried, dissolved in 2 ml acetonitrile (0.1% TFA), 4 ml of water
(0.1% TFA) was added, the solution was frozen in dry ice and
lyophilized for 48 h to give ﬁnal crude peptide in about 70% yield by
weight.
For the synthesis of biotinylated homologs used in binding studies
(Table 1) the resin was split into two parts (1:3) after completion of
the assembly of the V3 epitope. A spacer sequence, mainly Gly–Ser–
Gly, was built at the N-terminus of 25% of the peptide-resin followed
by incorporation of biotin at the N-terminus. The couplings were
carried out on the peptide synthesizer using the normal HOBT/HBTU
activation method.
Preparative HPLC puriﬁcation of linear peptide was carried out on a
Waters DeltaPak column 19×300 mm using a 20–50% acetonitrile/
water gradient in 80 min with a ﬂow rate of 5 ml/min and detection at
220 and 280 nm. Both solvent reservoirs contained 0.1% TFA. Usually
about 15 mg of crude peptide was dissolved in 1 ml of acetonitrile/
water (1:4) and injected onto the column. Analytical HPLC of the linear
peptides was carried out on a Zorbax Eclipse XDB-C8 column
4.6×150 mm using detection at 220 nm detection and 10–60%
acetonitrile/water gradient over 20 min with a ﬂow-rate of 1 ml/min.
The linear peptides used for cyclization were N90% homogeneous.
Disulﬁde bond formation
Peptides were cyclized using either ferricyanide mediated oxida-
tion, DMSO mediated oxidation or glutathione mediated oxidation
depending on the sequence and length of the peptide. In general the
reaction progress was monitored by electron spray ionization mass
spectrometry. In most of the cases the linear C4–V3 peptides were
cyclized using oxidized glutathione (GSSG) as the oxidant. In a typical
procedure, a solution of linear C4–V3 peptide (2.7 mg) dissolved in
3 ml of water containing 0.1% of TFAwas added dropwise to a solution
of GSSG (14 mg) in 80 ml of ammonium acetate (0.1 M, pH 7.9). The
combined solution was stirred overnight at room temperature. HPLC
analysis showed almost no change in retention time and the progress
of the reaction was monitored by MS analysis. After completion of the
reaction, the solution was acidiﬁed to pH 2.0 by dropwise addition of
0.5 ml of TFA, ﬁltered and the ﬁltrate was loaded onto a preparative
Waters C18 Delta Pak column. Product was eluted using a 10–50%
303A. Moseri et al. / Virology 401 (2010) 293–304acetonitrile/water gradient over 80 min. Both solvents contained 0.1%
TFA. The pure fractions were combined and lyophilized to result in
about 1.3 mg of pure cyclic peptide. The cyclic C4–V3 peptide was
N95% homogeneous as analyzed by HPLC and the MS difference
between linear and cyclic was 2 Da as expected.
Immunization of rabbits with V3 peptides
Twelveweek old female NewZealandwhite rabbits were purchased
from the animal breeding center at the Weizmann Institute of Science
(Rehovot, Israel). Animals were treated according to the guidelines and
under the supervision of the Animal Care and Use Committee. All the
work was done under the supervision of the veterinary resources
department. Animals were immunized up to ﬁve times at weeks 1, 4, 8,
13 and 37 with 250 μg of HPLC puriﬁed peptide in phosphate buffered
saline (PBS) or 250 μg gp120 in 50 mM Tris–HCl, 300 mM NaCl
administrated intramuscularly. Peptide was mixed at 1:1 volume/
volume ratio with Complete Freund's Adjuvant (CFA; 1 ml) at the ﬁrst
injection and Incomplete Freund's Adjuvant (IFA) in the second
injection; further boosts were administered with no adjuvant. Animals
were bled 10 days after each boost starting from the 3rd immunization.
Expression and puriﬁcation of gp120
The vector pSyn gp120 that encodes gp120JR-FL was kindly
provided by the NIH AIDS reagent program (http://www.aidsrea-
gent.org). From this vector, a gene encoding residues 88–492 of
gp120JR-FL i.e. 88–492gp120 was constructed and inserted into the
pIRES vector which was developed for high level expression in
HEK293 (Clontech, Mountain View, CA). This vector encodes the IgK
secretion signal, enabling secretion of the gp120 protein to the growth
medium and a 6× histidine tag followed by a Tobacco Etch Virus (TEV)
protease recognition site at the N-terminus of gp120. Additionally the
segments coding for the V1 and V2 variable loops were deleted and
replaced by a segment coding for Gly–Ala–Gly (GAG) and two
glycosylation sites were modiﬁed (N301Q and T388A). These
modiﬁcations have been reported to increase susceptibility to
neutralization by CD4-binding site antibodies (Koch et al., 2003).
This gp120 construct, 88–492gp120ΔV1/V2, N301Q, T388A (referred to
as gp120), was stably transfected into a mutated HEK293 cell line
lacking the gene for N-acetylglucosaminyltransferase I (Reeves et al.,
2002). The expressed proteins are homogenously glycosylated with
Man5GlcNAc2 glycans at sites normally occupied by complex or hybrid
glycans. The protein was puriﬁed initially on a 50 ml Cibacron Blue
Sepharose column (GE Healthcare), followed by a 5 ml HisTrap HP
column puriﬁcation (GE Healthcare). The eluted fraction was cleaved
by TEV protease, followed by an additional puriﬁcation on a Ni column
to remove the TEV and uncleaved gp120. Finally the protein was
puriﬁed on a superdex 200 16/60 (GE Healthcare). The homogenously
glycosylated 65 kDa protein was identiﬁed by SDS Polyacrylamide Gel
Electrophoresis and superdex 200 10/300 analytical gel ﬁltration.
Determining peptide binding titers by ELISA
To test the binding of the resulting antibodies to the immunizing
peptide, Reacti-Bind™ Streptavidin High Binding Capacity Coated
Plates clear, 96-wells were used (PIERCE Cat No. 15500). All
procedures were done at room temperature. Plates were washed
three times with PBS, 0.1% BSA, and 0.05% Tween-20 (wash buffer). A
volume of 100 μl of the V3 or C4 biotinylated peptide (Table 1) at 1 μg/
ml in wash buffer was added to each well and incubated for 2 h with
shaking. After rinsing the ELISA wells, serial dilutions of the serum in
wash buffer were added to each well and incubated for 1.5 h. This was
followed by several washes and 45 min incubation with 1:2500
dilutions of secondary antibodies in wash buffer (HRP-conjugated
donkey anti-rabbit-Jackson 711-035-152). The plates were washedand HRP substrate (TMB/E by Chemicon International) was added.
The reaction was stopped by adding 100 μl of 0.1% sodium ﬂuoride
and OD was read at 650 nm in a VersaMax microplate reader.
Alternatively Ni-column puriﬁed His-tagged gp120 (see above)
was coated onto HisGrab™ Nickel Coated, High Binding Capacity
Plates clear, 96-well (PIERCE Cat No 15142) for 2 h with shaking with
100 μl of 88–492gp120ΔV1/V2 at 10 μg/ml in PBS. Subsequent steps are
as described above for peptide ELISA.
In order to determine half-max binding values, OD values were
plotted against the serum dilution and ﬁtted using Origin software to
a one-site binding model. Data is presented as the reciprocal of the
serum dilution at half maximum binding, values were rounded to two
signiﬁcant ﬁgures.
When testing for binding to reduced V3 peptides, the peptides
were incubated overnight in wash buffer supplemented with 10 mM
DTT, followed by incubation on the plate with 10 mM DTT. Serum
dilutions and washes were done in wash buffer supplemented with
2 mM DTT. Linear peptide was treated the same as the control.
Neutralization assay
Pseudoviruses single round of infection-based neutralization assay
was carried out byMonogram Biosciences, Inc., South San Francisco as
previously described (Richman et al., 2003). Virus particles containing
virus envelope proteins were produced by co-transfecting HEK293
cells with a plasmid expressing HIV-1 primary isolates Env plus an HIV
genomic vector that contains the luciferase indicator gene. Murine
leukemia virus (MLV) Env plasmid was used as a negative control to
assess non-speciﬁc neutralization. Recombinant pseudotyped viruses
were harvested 48 h post-transfection and incubated for 1 h at 37 °C
with serial two-fold dilutions of heat-inactivated rabbit sera starting
at 1:10. The virus/serum dilutions were incubated with U87 CD4+,
CCR5+ and CXCR4+ cells. Virus infectivity was determined 72 h post-
inoculation by measuring the amount of luciferase activity expressed in
infected cells. Neutralizing activity is displayed as the percent inhibition
of viral replication (luciferase activity) at each antibody dilution
compared with no antibody sample, % inhibition={1−[luciferase+Ab/
luciferase−Ab]}*100. Titerswere calculated as the reciprocal of the serum
dilution conferring 50% inhibition.
Statistical analysis
In order to assess the difference in binding to the immunizing V3
peptide and gp120 a one sample T-test for a hypothetical mean value of
1wasused. Unpaired T-test to compare twomeanswas used to evaluate
differences in binding to cyclic vs. reduced V3 peptide. Analysis was
performed using the GraphPad QuickCalc Internet tools (http://www.
graphpad.com/quickcalcs/). P-valueb0.05 was considered signiﬁcant.
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